IndustryCompany release

Ultragenyx cuts about 20% of staff and sells two priority review vouchers for $413M

🇺🇸 Ultragenyx Pharmaceutical Inc. (RARE) · Tue 03 Nov 2026

After FDA approvals for GENGLYCOS and FAYUVI, Ultragenyx is restructuring, ending two programmes and reaffirming a target of profitability in 2027.

Ultragenyx Pharmaceutical reported third-quarter revenue of $173 million and a net loss of $118 million on 3 November 2026. Alongside the results, the company announced a headcount reduction of roughly 20%.

The restructuring also involves pipeline decisions. Ultragenyx is winding down studies of GTX-102 and terminating development of UX701, its candidate for Wilson disease.

The cuts follow two US approvals in quick succession. The FDA approved GENGLYCOS for glycogen storage disease type Ia (GSDIa) in August, and FAYUVI for Sanfilippo syndrome type A in September.

Each approval earned the company a priority review voucher. Ultragenyx has agreed to sell both for a combined $413 million. As background, such vouchers entitle the holder to a shortened FDA review for a later application and can be transferred to other companies.

The company reaffirmed its goal of reaching profitability in 2027. The summary provided does not give further detail on the timing of the cuts, the sale counterparties or the financial effect of the restructuring.

What it means for your team

  • Regulatory teams tracking GENGLYCOS and FAYUVI should expect the company to concentrate on launching these two approved products.
  • The end of UX701 development and the wind-down of GTX-102 studies remove two programmes from the Wilson disease and related rare-disease pipelines.
  • A roughly 20% reduction in staff may affect company contacts and capacity; partners and PV teams should confirm points of contact.
  • The $413 million voucher sales show that priority review vouchers can be monetised, which affects how companies fund rare-disease development.

Company's press release (SEC filing): Ultragenyx Pharmaceutical Inc. ↗

Article written by VigiEye from the official source (Ultragenyx Pharmaceutical Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →